



Natco Pharma Limited

Regd. Off. : 'NATCO HOUSE', Road No. 2, Banjara Hills, Hyderabad - 500034.
Telangana, INDIA. Tel : +91 40 23547532, Fax : +91 40 23548243
CIN : L24230TG1981PLC003201, www.natcopharma.co.in

Ref:PR/23/2015

Press Release

NATCO RECEIVES GENERIC SOFOSBUVIR (SOVALDI®) APPROVAL FOR INDIA

Hyderabad, India, March 12th, 2015

Natco Pharma Limited (NSE: NATCOPHARM; BSE: 524816) is pleased to announce that it is the 1st company in India to get approval for generic sofosbuvir tablets, 400mg, from Drugs Controller General (India). Sofosbuvir is a medicine used for chronic hepatitis C infection and sold globally by Gilead Sciences, Inc., under its brand Sovaldi®.

Natco will market generic sofosbuvir under its brand HEPCINAT and through strategic partners in India. Natco plans to price its generic medicine at an MRP of INR 19,900 for a bottle of 28 tablets and expects to launch in India very soon. Natco had recently signed a non-exclusive licensing agreement with Gilead Sciences, to manufacture and sell generic versions of its chronic hepatitis C medicines in 91 developing countries.

Forwarded for favor of publication

For NATCO Pharma Limited

A handwritten signature in black ink that reads "M Adinarayana".

M Adinarayana
Company Secretary &
Vice President (Legal & Corp Affairs)